This article explores the history, progress and contributions made by Mikhail Blagosklonny. It aims to comprehensively outline his past and current achievements and contributions and his passionate tendencies regarding his niche in the future.
Mikhail Blagosklonny, formerly a professor of oncology at the Roswell Park Cancer Institute in New York, is a scientist who is devoted to the subject of cancer and aging. Having published 300 research articles, news articles and reviews, Blagosklonny’s research areas range from molecular and cellular biology to clinical investigations. Mikhail Blagosklonny was granted a M.D. in internal medicine after completing studies at First Pavlov State Medical University of St. Peterburg. He later pursued his PhD in experimental medicine and cardiology from the same University and more information click here.
His career accomplishments include being appointed as an associate professor of medicine at New York Medical College, Valhalla, NY. He also took a position as a senior scientist at Ordway Research Institute (Albany, New York). In 2009, Blagosklonny was appointed professor of oncology at Roswell Park Cancer Institute. He is the founding editor and editor in chief of Aging and Cell Cycle. He is also an associate editor of Cancer Biology & Therapy and serves as a member of the editorial board of Cell Death & Differentiation. He has been involved in the editorial teams for the following publications: International Journal of Cancer, The American Journal of Pathology and PLOS ONE, Cancer Biology & Therapy, and Cancer Research and learn more about Mikhail.
Blogosklonny has researched into cancer and targeted cancer therapies, the objective of these therapies is to protect normal cells from damage. He has also researched into the basic and complex mechanisms of aging (bio-gerontology), including anti-aging drugs and Mikhail lacrosse camp.
He has contributed to the medical industry through much of his work including his work on Rapamycin and aging. Blagosklonny has come up with a hypothesis regarding the possible role of TOR signaling in aging and cancer. As a result of researching into bio-gerontology, he has proposed that using Rapamycin, a drug that adds longevity, can be a possible way to extend life as a part of treatment for cancer. He is viewed as a dedicated advocate for the Rapamycin drug and read full article.
Mikhail Blagosklonny has authored the aging hyper-function theory. Alongside, he has also contributed to cell cyclotherapy and chemotherapeutic engineering by formulating his observations, hypothesis and speculations. Having a keen interest in oncology, he primarily believes in the possibility of controlling aging and cancer. Precisely, Mikhail Blagosklonny believes that cancer can be cured and therefore he suggests the use of Rapamycin, as aforementioned. As an author, physician, scientist and a professor, he cites his love for humanity and his envisioning of a disease-free community as his motivation behind his relentless efforts invested in these fields of study. His passion continues to boost his motivation and nothing short of a breakthrough is expected from him by his academic beneficiaries and peers.
The highly devoted scientist is known to have cited over 25,0000 in his research work and thus holds an h-index of 83. He has progressed his career standing through a number of highly acclaimed appointments. He is currently pursuing his study in longevity of life and other cancer related studies vigorously.